George A. Eldridge, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 14,229 shares at $26.77 ($382K) on 2024-04-10, disclosed to the SEC on 2024-04-12.
Scheduled sale ($382k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.77 | 6,729 | $180K | 47.2% |
| 2 | $26.77 | 6,729 | $180K | 47.2% |
| 3 | $27.56 | 771 | $21K | 5.6% |
| Total | $26.81 avg | 14,229 | $382K | 100% |
| Filing → |
| AVTE | SELL | 2024-03-14 | $204K | — | Filing → |
| AVTE | SELL | 2024-03-11 | $736K | — | Filing → |
| AVTE | SELL | 2022-12-13 | $479K | — | Filing → |